Positive clinical trial results typically lead to increased investor confidence in a pharmaceutical company's pipeline, potentially driving up stock prices. The announcement of successful Phase 2 data and the progression to Phase 3 studies indicate significant milestones for Arrowhead Pharmaceuticals, likely positively impacting its stock in the short term.